Tags

Type your tag names separated by a space and hit enter

The advanced glycation end product methylglyoxal-derived hydroimidazolone-1 and early signs of atherosclerosis in childhood diabetes.
Diab Vasc Dis Res. 2015 Mar; 12(2):139-45.DV

Abstract

BACKGROUND

Advanced protein glycation is an important mechanism for the development of late diabetic complications including atherosclerosis. Methylglyoxal-derived hydroimidazolone-1 is the most abundant advanced glycation end product in human plasma.

AIM

To investigate the relationship between methylglyoxal-derived hydroimidazolone-1 and early signs of atherosclerosis in children and adolescents with type 1 diabetes and healthy controls.

METHODS

A total of 314 diabetes patients aged 8-18 years were compared with 120 healthy controls. Serum methylglyoxal-derived hydroimidazolone-1 was measured by immunoassay. Atherosclerosis was evaluated by assessing carotid intima-media thickness by ultrasound, arterial stiffness by Young's modulus and inflammation by C-reactive protein.

RESULTS

Methylglyoxal-derived hydroimidazolone-1 was significantly increased in the diabetes group compared with controls, 155.3 (standard deviation (SD) = 41.0) versus 143.0 (SD = 35.1) U/mL, p = 0.003, as was C-reactive protein, median 0.51 (0.27, 1.83) versus 0.31 (0.19, 0.67) mg/L, p < 0.001. There was no significant difference between the groups regarding carotid intima-media thickness or Young's modulus. Multiple regression analysis showed a significant positive association between methylglyoxal-derived hydroimidazolone-1 and C-reactive protein in the diabetes group.

CONCLUSION

Serum levels of methylglyoxal-derived hydroimidazolone-1 in diabetes patients are increased and associated with low-grade inflammation, but not yet arterial stiffness or wall thickness. This indicates that methylglyoxal-derived hydroimidazolone-1 may be important in the early phase of the accelerated atherosclerotic process in diabetes.

Authors+Show Affiliations

Department of Pediatrics, Oslo University Hospital, Oslo, Norway Faculty of Medicine, University of Oslo, Oslo, Norway Oslo Diabetes Research Centre, Oslo, Norway martin.heier@medisin.uio.no.Faculty of Medicine, University of Oslo, Oslo, Norway Oslo Diabetes Research Centre, Oslo, Norway Akershus University Hospital, Lørenskog, Norway.Faculty of Medicine, University of Oslo, Oslo, Norway Hormone Laboratory, Oslo University Hospital, Oslo, Norway.Faculty of Medicine, University of Oslo, Oslo, Norway Center for Clinical Heart Research and Department of Cardiology, Oslo University Hospital, Oslo, Norway.Faculty of Medicine, University of Oslo, Oslo, Norway Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.Department of Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway.Faculty of Medicine, University of Oslo, Oslo, Norway Oslo Diabetes Research Centre, Oslo, Norway Department of Endocrinology, Oslo University Hospital, Oslo, Norway.Department of Pediatrics, Oslo University Hospital, Oslo, Norway Faculty of Medicine, University of Oslo, Oslo, Norway Oslo Diabetes Research Centre, Oslo, Norway.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25616705

Citation

Heier, Martin, et al. "The Advanced Glycation End Product Methylglyoxal-derived Hydroimidazolone-1 and Early Signs of Atherosclerosis in Childhood Diabetes." Diabetes & Vascular Disease Research, vol. 12, no. 2, 2015, pp. 139-45.
Heier M, Margeirsdottir HD, Torjesen PA, et al. The advanced glycation end product methylglyoxal-derived hydroimidazolone-1 and early signs of atherosclerosis in childhood diabetes. Diab Vasc Dis Res. 2015;12(2):139-45.
Heier, M., Margeirsdottir, H. D., Torjesen, P. A., Seljeflot, I., Stensæth, K. H., Gaarder, M., Brunborg, C., Hanssen, K. F., & Dahl-Jørgensen, K. (2015). The advanced glycation end product methylglyoxal-derived hydroimidazolone-1 and early signs of atherosclerosis in childhood diabetes. Diabetes & Vascular Disease Research, 12(2), 139-45. https://doi.org/10.1177/1479164114560910
Heier M, et al. The Advanced Glycation End Product Methylglyoxal-derived Hydroimidazolone-1 and Early Signs of Atherosclerosis in Childhood Diabetes. Diab Vasc Dis Res. 2015;12(2):139-45. PubMed PMID: 25616705.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The advanced glycation end product methylglyoxal-derived hydroimidazolone-1 and early signs of atherosclerosis in childhood diabetes. AU - Heier,Martin, AU - Margeirsdottir,Hanna Dis, AU - Torjesen,Peter Abusdal, AU - Seljeflot,Ingebjørg, AU - Stensæth,Knut Haakon, AU - Gaarder,Mario, AU - Brunborg,Cathrine, AU - Hanssen,Kristian Folkvord, AU - Dahl-Jørgensen,Knut, Y1 - 2015/01/23/ PY - 2015/1/25/entrez PY - 2015/1/27/pubmed PY - 2015/12/15/medline KW - C-reactive protein KW - Diabetes mellitus type 1 KW - advanced glycation end products KW - atherosclerosis SP - 139 EP - 45 JF - Diabetes & vascular disease research JO - Diab Vasc Dis Res VL - 12 IS - 2 N2 - BACKGROUND: Advanced protein glycation is an important mechanism for the development of late diabetic complications including atherosclerosis. Methylglyoxal-derived hydroimidazolone-1 is the most abundant advanced glycation end product in human plasma. AIM: To investigate the relationship between methylglyoxal-derived hydroimidazolone-1 and early signs of atherosclerosis in children and adolescents with type 1 diabetes and healthy controls. METHODS: A total of 314 diabetes patients aged 8-18 years were compared with 120 healthy controls. Serum methylglyoxal-derived hydroimidazolone-1 was measured by immunoassay. Atherosclerosis was evaluated by assessing carotid intima-media thickness by ultrasound, arterial stiffness by Young's modulus and inflammation by C-reactive protein. RESULTS: Methylglyoxal-derived hydroimidazolone-1 was significantly increased in the diabetes group compared with controls, 155.3 (standard deviation (SD) = 41.0) versus 143.0 (SD = 35.1) U/mL, p = 0.003, as was C-reactive protein, median 0.51 (0.27, 1.83) versus 0.31 (0.19, 0.67) mg/L, p < 0.001. There was no significant difference between the groups regarding carotid intima-media thickness or Young's modulus. Multiple regression analysis showed a significant positive association between methylglyoxal-derived hydroimidazolone-1 and C-reactive protein in the diabetes group. CONCLUSION: Serum levels of methylglyoxal-derived hydroimidazolone-1 in diabetes patients are increased and associated with low-grade inflammation, but not yet arterial stiffness or wall thickness. This indicates that methylglyoxal-derived hydroimidazolone-1 may be important in the early phase of the accelerated atherosclerotic process in diabetes. SN - 1752-8984 UR - https://www.unboundmedicine.com/medline/citation/25616705/The_advanced_glycation_end_product_methylglyoxal_derived_hydroimidazolone_1_and_early_signs_of_atherosclerosis_in_childhood_diabetes_ L2 - http://journals.sagepub.com/doi/full/10.1177/1479164114560910?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -